# Eloxx Pharmaceuticals, Inc.

**ELOX**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001035354


# None

**No letter**

2 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $5.3M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | late filer, thin data, degenerate inputs;...<br>not computable: dilution, short runway, distress |
| **Inputs computable** | 2 of 14 |
| **Graded from** | filings received through Mar 17, 2026<br>218 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $13.27<br>2026-10-20; market equity $53.6M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 17, 2026*

-License Agreements-License Agreement between Eloxx and Almirall." The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *prior invested-capital observation is 1096 days earlier* | | | | | | |
| Accruals ratio | not computable | (6.6%) | | | | |
| *prior assets observation is 1096 days earlier* | | | | | | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 97.2** | | | | | | |
| Twelve-month failure probability | not computable | 0.06% | | | | |
| *four consecutive discrete net-income quarters are required; found 4* | | | | | | |
| Altman Z double-prime | (209.70) | (0.30) | | 98.3 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 0.31x | 2.96x | | 96.1 | 840 | 2025-12-31 |
| **Growth and financing** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 3* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 11* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | not computable | 2.1% | | | | |
| *four consecutive annual observations are required* | | | | | | |
| Net share issuance, one year | not computable | 2.4% | | | | |
| *prior share count is 1081 days earlier* | | | | | | |

## Warnings

*4 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Late filer | found 4 NT 10-K/Q filings in the last eight quarters |
| Thin data | 2 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |
| Fortress balance sheet | cash minus debt is 3,785,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-10-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | not computable | 8.0% | |
| Distance from 52-week high | (37.0%) | (29.7%) | 41 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (59.8%) | (1.0%) | 11 |
| Book value to price | 0.87 | 0.28 | 83 |
| Sales to price | 0.00 | 0.30 | 0 |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | not computable | (0.13) | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 71 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $482,451 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$6.4M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$6.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 4 | total debt | us-gaap:LongTermDebt | $1.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 5 | book equity | us-gaap:StockholdersEquity | -$11.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $4.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 7 | total debt | us-gaap:LongTermDebt | $11.7M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 8 | book equity | us-gaap:StockholdersEquity | -$10.7M | 2022-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $19.2M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 10 | net income | us-gaap:NetIncomeLoss | -$6.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.3M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 12 | assets | us-gaap:Assets | $5.3M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 13 | assets | us-gaap:Assets | $21.1M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 14 | current assets | us-gaap:AssetsCurrent | $5.3M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $17.2M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$300.6M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 17 | liabilities | us-gaap:Liabilities | $17.2M | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 18 | depreciation amortization | us-gaap:Depreciation | $0 | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 19 | operating income | us-gaap:OperatingIncomeLoss | -$20.4M | 2017-12-31 | 2020-03-06 | 10-K | 20-009148 |
| 20 | interest expense | us-gaap:InterestAndDebtExpense | $824,000 | 2017-12-31 | 2018-03-16 | 10-K | 18-086028 |
| 21 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-03-17 | 10-K | 26-108687 |
| 22 | revenue | us-gaap:Revenues | $182,229 | 2014-06-30 | 2016-10-13 | 10-K | 16-128038 |
| 23 | revenue | us-gaap:Revenues | $200,000 | 2012-06-30 | 2012-10-26 | 10-K/A | 12-057875 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $66,000 | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 25 | depreciation amortization | us-gaap:Depreciation | $77,000 | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 26 | operating income | us-gaap:OperatingIncomeLoss | -$34.4M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 27 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$36.1M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 28 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 29 | current assets | us-gaap:AssetsCurrent | $20.1M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 30 | current liabilities | us-gaap:LiabilitiesCurrent | $23.1M | 2022-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 31 | current assets | us-gaap:AssetsCurrent | $43.5M | 2021-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 32 | current liabilities | us-gaap:LiabilitiesCurrent | $10.0M | 2021-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 33 | assets | us-gaap:Assets | $45.1M | 2021-12-31 | 2023-03-31 | 10-K | 23-011360 |
| 34 | assets | us-gaap:Assets | $26.5M | 2020-12-31 | 2022-03-30 | 10-K | 22-012683 |
| 35 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 5,071,935 | 2026-03-12 | 2026-03-17 | 10-K | 26-108687 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,166,356 | 2023-03-27 | 2023-03-31 | 10-K | 23-011360 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.